MIP Diagnostics

MIP Diagnostics

A New World of Diagnostics with nanoMIPs

2020
Year invested

MIP is focussed on developing synthetic antibodies made from molecularly imprinted polymers (MIPs) that can be used in applications where antibodies traditionally struggle. MIPs have successfully been created and deployed against all major target classes including peptides, proteins and other macromolecular structures, as well as smaller chemical entities such as drugs, their metabolites and commonly used biochemical species such as enzyme cofactors.

Meet the team

Related articles

The time to put the spotlight on Healthcare is now

As Covid-19 continues to dominate the global agenda, early-stage UK technology companies in the healthcare and...

Downing LLP launches 'knowledge intensive' EIS fund to fuel entrepreneurial healthcare businesses in wake of Covid-19

Specialist tax-efficient investment manager Downing LLP is pleased to announce the launch of a new Enterprise ...

How to survive and thrive in 2021 as a VC firm according to Downing Ventures - article

In 2021, it has never been more important for venture capital firms to be able to differentiate.